The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent dilution. See Abreview.
Use at an assay dependent concentration.
Use a concentration of 0.1 - 0.3 µg/ml. Detects a band of approximately 17 kDa (predicted molecular weight: 18 kDa). Transfer onto PVDF membrane and block in 3 % milk. Incubate primary antibody with membrane at room temperature.
Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3 and SUMO4 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2 or CBX4. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation.
Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus.
Protein modification; protein sumoylation.
Belongs to the ubiquitin-conjugating enzyme family.
Nucleus. Cytoplasm. Mainly nuclear. In spermatocytes, localizes in synaptonemal complexes. Recruited by BCL11A into the nuclear body.
Ab21193 (0.3ug/ml) staining human UBE2I in human kidney by immunohistochemistry using paraffin embedded tissue.
Microwaved antigen retrieval with Tris/EDTA buffer pH9, HRP-staining.
Immunocytochemistry/ Immunofluorescence - Anti-UBE2I / UBC9 antibody (ab21193)This image is courtesy of an abreview submitted by Motomasa Ihara
ab21193 staining UBE2I / UBC9 in mouse oocyte by Immunocytochemistry. The cells were fixed in paraformaldehyde, permeabilized in 0.1% Tween and blocked in 0.1% BSA for 30 minutes at 25°C. The primary antibody was diluted 1/50 and incubated with sample for 1 hour at 25°C. A Cy5® conjugated Donkey polyclonal to goat, diluted 1/400 was used as the secondary.
Fang S et al. Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin. Oncotarget8:49783-49795 (2017).
Read more (PubMed: 28572537) »
Xu J et al. BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells. Int J Chronic Dis Ther2:31-38 (2016).
Read more (PubMed: 28164176) »